td

(redirected from tetanus and diphtheria toxoids)
Also found in: Dictionary, Thesaurus, Medical, Financial.
Related to tetanus and diphtheria toxoids: varicella, pertussis

TD

(electricity)

td

(networking)
The country code for Chad.
References in periodicals archive ?
To prevent tetanus, ACIP recommends a 5-dose series of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) for children at ages 2, 4, 6, 15-18 months, and 4-6 years, followed by 1 dose of tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) for adolescents aged 11-12 years.
Studies on short intervals (i.e., within 21 days or [less than or equal to] 2 years) between receipt of tetanus and diphtheria toxoids (Td) and Tdap or Tdap-inactivated polio vaccine in healthy, nonpregnant adolescents and adults found no serious adverse events (21-23).
In March 2006, the CDC's Advisory Committee on Immunization Practices (ACIP) issued recommendations on replacing the adolescent tetanus and diphtheria toxoids (Td) with Tdap.
In early June, the CDC issued a statement prioritizing the use of Td vaccine for wound management, travel to diphtheria-endemic countries, people who have received fewer than three doses of vaccine containing tetanus and diphtheria toxoids (primary series), and pregnant women who have not been vaccinated within the preceding 10 years.
The safety and reactogenicity profiles of Boostrix generally were similar to currently available tetanus and diphtheria toxoids (Td) vaccine.
The adult formula of the tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) can be given to children and adolescents starting at 18 months after a children's formula tetanus and diphtheria vaccine, said Dr.
* Use of tetanus and diphtheria toxoids, and acellular pertussis (Tdap) vaccine among children aged 7 through 10 years who are incompletely vaccinated against pertussis is addressed, and reference to a specified interval between tetanus and diphtheria toxoids (Td) and Tdap vaccination has been removed (5).
A total of 4.6% of those who received Boostrix reported grade-3 pain, compared with 4.0% of 1,034 who received a control (tetanus and diphtheria toxoids adsorbed for adult use [Td] vaccine, made by Massachusetts Public Health Biologic Laboratories).